Antibody-Mediated Rejection: Addressing the Underlying Issues for Improved Patient Outcomes

Program Overview

The goal of this activity is to provide education about AMR treatment principles, guidelines, and emerging therapies. Faculty will discuss the genesis of alloantibody production and how it contributes to graft loss, as well as unmet needs in AMR therapies. An experienced patient with AMR provides insights for transplant clinicians to consider when treating their patients with AMR.

Credit Expired
CE Credit Expired
Expires: August 6, 2021

Target Audience

This activity is intended for clinicians actively engaged in managing antibody-mediated rejection (AMR) in transplant patients, including transplant physician, surgeons, NPs, and PAs with an interest in transplant

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Summarize the pathophysiology of antibody-mediated rejection (AMR), including the role of the complement system and cytokine pathways in disease pathogenesis
  • Evaluate the efficacy and safety data supporting existing and emerging treatment options for AMR, including anti-complement and anti-cytokine strategies
  • Select appropriate treatments for patients with AMR to improve allograft survival

Activity Faculty

Robert Montgomery 2019 photo_Crop

Robert A. Montgomery, MD, DPhil, FACS (Chair)

Professor of Surgery
Director
, NYU Langone Transplant Institute
New York, NY

Djamali2

Arjang Djamali, MD, MS, FASN

Professor, Medicine and Surgery
Head, Division of Nephrology
Department of Medicine
University of Wisconsin
School of Medicine and Public Health
Madison, WI

Jordan

Stanley C. Jordan, MD, FASN, FAST

Director, Nephrology & Transplant Immunology
Medical Director, Kidney Transplant Program
Cedars-Sinai Medical Center
Professor, Pediatrics & Medicine
David Geffen School of Medicine at UCLA
Los Angeles, CA

Michael Kronman (Patient)

Supporter Statement

Provider Statement

Disclosure of Financial Relationships

Faculty

Planners and Managers

Method of Participation and Request for Credit

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer Statement

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Copyright Statement

© Copyright 2024. All rights reserved. Developed and managed by RMEI Medical Education, LLC. Laurel Office Plaza | 101 Laurel Road, Suite 200 | Voorhees, NJ 08043 | www.RMEI.com | (866) 770-RMEI

Subscribe

Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources